FDA Acknowledgment Letter to Kyle Cummings
Summary
The FDA has posted an acknowledgment letter sent to Kyle Cummings regarding a submission. The letter is from the FDA's Division of Management and Budget (DMB) and was authored by CDRH. A redacted version is available for download.
What changed
The FDA has published an acknowledgment letter addressed to Kyle Cummings, indicating receipt of a submission. The letter originates from the FDA's Division of Management and Budget (DMB) and was prepared by the Center for Devices and Radiological Health (CDRH). A redacted version of this acknowledgment letter is publicly available.
This document serves as a notification of receipt and does not impose new regulatory obligations or provide substantive guidance. Compliance officers should note this as a procedural update related to a specific submission, with no immediate action required unless directly involved with the referenced submission.
Source document (simplified)
Content
There are no documents available to view or download
Attachments 2
Acknowledgment Letter from FDA DMB to Kyle Cummings
Restricted: Personally Identifiable Information
More Information
- Author(s) CDRH
Acknowledgment Letter from FDA DMB to Kyle Cummings - Redacted
More Information
- Author(s) CDRH
Download
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Healthcare alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when Regs.gov: Food and Drug Administration publishes new changes.